Member Info for rp6577

MMS dropped the ask a lot, but the bid not moved much. Very few trades appear to have gone through yet

Any ideas as to when we might see a CPR for Tanzania? I do think Lorna should update us on this. If I was her, getting that report out would be my highest priority. They mentioned Spring from memory a little while back. It would be good to know whether it has been commissioned yet

Haven’t seen the new Shard note, but in their last one the estimated 2026 revenue was £3.28m with EBITDA of -0.25m.

If we hit that (and it sounds like Adrian thinks we will - with a bit of luck) that would be great.

What will be interesting is to see what our margins are for that year. With a lot of labour costs being paid for by grants, we could get a glimpse of positive EBITDA which would be big.

Back in 2021 the revenue was c.£4m and EBITDA was -0.52m. The market cap at that time was around £28m.

Obviously interest rates were a lot lower and biotech was having a boom, but we would certainly see a much higher market cap than the £7m we currently have.

Picked up another 5k at 6p

Feels a little light on info? I was hoping for a bit more detail on the number s. Also some forward guidance would be good. What is their expectation a for the next year now they have the grant money?

Fingers crossed

WG - is it possible to short this stock?

The reason I’m asking is that if you are not short, what is the point constantly posting and just annoying people?

Even if you have made valid points etc, people on this board don’t need to hear it

Hopefully a good trade my update next week which shows some good margins. I then think the summer update will be when things kick into gear, when we start to see the various grants kick in and massively reduce labour costs and increase margins further.

That will then be followed by a licensing agreement with the NCI towards the end of the year. Potentially also with other big pharma following validation by the NCI.

This year will be huge. The final bit of patience required.

Just buy as much as you can while you can…

Well I picked up another £10k of shares

Their margins are going to look great over this next year. This is another grant that can be spent on labour costs.

Also I love how they will jointly own the antibody. Once developed they will most likely license out to a clinical stage biotech company who will conduct trials. This usually includes an upfront payment, along with milestones as it goes through the clinical stages.

You start building up a portfolio of these over time and it starts to get very interesting.

I mean that is pretty great. This company just has an incredible future ahead of it

I’m now at 2.04m shares. Looking forward to the inevitable move higher

I think the market cap historically peaked around the 40m mark. However, we’ve come a long way R&D wise since then.

Getting back to that market cap is the initial target

Great update. They clearly see the potential. They are also not in it for a quick trade of 20%. They will be looking for multiples.

I’m looking forward to seeing the share price migrate back up towards highs over time

The gas storage estimate valuation is huge. Any kind of advancement of that would send the share price soaring

Need that CPR. If they can tell us there is some serious recoverable BCF there, that’s when people can actually put a proper value on it

Looking very positive here

Time to get some proper momentum back. Flushed out a lot of sellers, so now should have a solid base

It is certainly getting frustrating.

Is it perhaps partly linked to the revenue quoted in the recent RNS? It’s broadly in line with expectations but given they did £1.2m in the first half I felt 1.9m was a bit light for the full year (although they said at least 1.90).

The real target is a big licensing deal later in the year, but if we can get to some profitability then we can also just get a general rerate with a valuation based on multiples of EBITDA

Fair play to Lorna, moving quickly to make that BlueStar investment was a good move. Otherwise we would have been sitting in silence praying for Tanzania the last few months.

Having a revenue stream should help when looking into the development finance required to build out Rukwa